The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia

Leukemia Research
D E HoggeA E Frankel

Abstract

Addition of cytosine arabinoside (Ara-C) to truncated diphtheria toxin (DT388) fused to granulocyte macrophage-colony stimulating factor (GMCSF) or interleukin-3 (IL3) was studied in a NOD/SCID mouse model of human AML. Ara-C alone did not reduce the % human AML cells in mouse bone marrow (BM). DT388IL3 or DT388GMCSF alone reduced but did not eradicate engraftment for two of four and two of three samples, respectively. In contrast, Ara-C with DT388IL3 eliminated AML from mouse BM with one of four samples while DT388GMCSF with Ara-C eliminated or reduced AML cells as compared to mice receiving either agent alone with two of three samples.

References

Apr 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M ProchazkaE H Leiter
May 15, 1991·Journal of the National Cancer Institute·R PirkerL Havelec
Oct 4, 1989·Journal of the National Cancer Institute·D FitzGerald, I Pastan
Sep 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P DutcherP H Wiernik

❮ Previous
Next ❯

Citations

Sep 19, 2008·Leukemia·N MisaghianJ A McCubrey
Nov 6, 2007·Trends in Molecular Medicine·Daniela S Krause, Richard A Van Etten
Nov 8, 2017·Language and Speech·Alison BehrmanMariola Moeyaert
Aug 30, 2019·Expert Review of Clinical Pharmacology·Minas P EconomidesNaveen Pemmaraju
Mar 13, 2019·Drugs·Yahiya Y Syed
May 19, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Victor PallarèsRamon Mangues

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.